# S. Vincent Rajkumar

Source: https://onco.cc/people/vincent-rajkumar/  
OnCo record `vincent-rajkumar` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Myeloma expert who wrote the diagnostic criteria the field uses and a persistent critic of drug prices.

## Summary

S. Vincent Rajkumar is Professor of Medicine in the Division of Hematology at Mayo Clinic and editor-in-chief of Blood Cancer Journal. A haematologist specialising in multiple myeloma and plasma cell disorders, he led the International Myeloma Working Group's updated diagnostic criteria, the criteria the field uses, and the randomised trials establishing lenalidomide-dexamethasone dosing. His papers include the Lancet Oncology report of the International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma and the Lancet Oncology open-label randomised trial of lenalidomide plus high-dose versus low-dose dexamethasone as initial therapy for newly diagnosed myeloma. He is also a persistent critic of drug prices, and his record links to BCMA.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medicine, Division of Hematology, Mayo Clinic
- Specialisms: Multiple myeloma; Plasma cell disorders; Drug pricing

## Sources

- Mayo Clinic research faculty: https://www.mayo.edu/research/faculty
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Rajkumar%20SV%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=S.%20Vincent%20Rajkumar

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- institutions: [Mayo Clinic](https://onco.cc/institutions/mayo-clinic/)
- terms: [MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)](https://onco.cc/terms/mrd-negativity-myeloma/), [R-ISS / R2-ISS staging](https://onco.cc/terms/r-iss/)

---
JSON: https://onco.cc/api/v1/entities/vincent-rajkumar.json